Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II proof-of-concept study of GRC 17536 in painful diabetic peripheral neuropathy
2011-005879-16Phase 2Completed
- Sponsor
- Glenmark Pharmaceuticals SA
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GRC-17536 in diabetic polyneuropathy (DPN) (3 arms), sponsored by Glenmark Pharmaceuticals SA. Primary endpoints: Change in mean 24-hour average pain intensity score from baseline to end of week 2, Change in mean 24-hour average pain intensity score from end of week 2 to end of week 4 and 1 more. Started Jan 2012; status: completed.
02
Drugs
GRC-17536
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2011-005879-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005879-16.